MedPath

Post Market Clinical Follow-Up Study of the EVOLUTION® Total Knee Arthroplasty System with Cruciate Sacrificing Inserts (Project AMETHYST)

Conditions
M24
M25
Other specific joint derangements
Other joint disorders, not elsewhere classified
Registration Number
DRKS00011069
Lead Sponsor
MicroPort Orthopedics Inc.USA
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
150
Inclusion Criteria

To be included in the study, subjects must meet all of the following criteria:
- Has previously undergone primary TKA for any of the following:
- non-inflammatory degenerative joint disease including osteoarthritis, traumatic arthritis, or avascular necrosis;
- inflammatory degenerative joint disease including rheumatoid arthritis;
- correction of functional deformity.
- Subject was implanted with the specified combination of components
- Subject is willing and able to complete required study visits and assessments
- Subject plans to be available through the 10 year postoperative follow-up visit
- Subject is willing to sign the approved Informed Consent document
- Subject must be at least 2 years post TKA prior to informed consent.
Previously implanted bilateral subjects can have both TKAs enrolled in the study provided: 1) the specified combination of components were implanted in both, 2) all other aspects of the Inclusion/Exclusion Criteria are satisfied, 3) enrollment does not exceed the subject count specified in the Clinical Trial Agreement, and 4) the subject agrees to a second Informed Consent document specific to the second TKA. Prospective enrollment of a previously unimplanted knee is not permitted in this study.

Exclusion Criteria

Subjects will be excluded if they meet any of the following criteria:
- Subject was skeletally immature (less than 21 years of age) at time of implantation
- Subject is currently enrolled in another clinical investigation which could affect the endpoints of this protocol
- Subject is unwilling or unable to sign the Informed Consent document
- Subject has documented substance abuse issues
- Subject has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study
- Subject has a body mass index (BMI) of greater than 40
- Subject is currently incarcerated or has impending incarceration

Study & Design

Study Type
observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary endpoints are Kaplan-Meier estimates of survivorship for all components at each follow-up interval out to 10 years. This is done by capturing whether a revision is done yes/no, when the patient comes in for a routine follow-up visit (2-5, 5-7 and 10 years post-operatively).
Secondary Outcome Measures
NameTimeMethod
Characterization of total functional scores for subjects, as assessed by KOOS Scores and EQ-5D-3L Scores. These questionnaires are filled out by the patient pre-operatively and 2-5, 5-7, and 10 years post-operatively.<br>Proportion of subjects reporting being satisfied with their TKA and proportion of subjects who would have their procedure performed again as assessed by questionnaire 2-5, 5-7, and 10 years post-operatively.<br>A summary of the number and size of radiolucencies in zones surrounding implanted components as assessed by evaluating radiographs taken 2-5, 5-7, and 10 years post-operatively.
© Copyright 2025. All Rights Reserved by MedPath